Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936480 · ClinicalTrials.gov registry record · Phase 4
Genetics of QT Response to Moxifloxacin
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT01936480: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01936480 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01936480, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in healthy subjects using moxifloxacin.
Interventions
- DRUG Moxifloxacin 400mg once time
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-10 |
| Est. Completion | 2019-06-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01936480
The ClinicalTrials.gov registry entry for NCT01936480 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Moxifloxacin 400mg once time is the first listed.
NCT01936480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01936480 about?
NCT01936480 is a clinical study titled "Genetics of QT Response to Moxifloxacin". The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in healthy subjects using moxifloxacin.
What is the current status of trial NCT01936480?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2013-10. Estimated completion is 2019-06-19.
What interventions are being tested in trial NCT01936480?
The interventions under investigation include: Moxifloxacin 400mg once time (DRUG).
Who is sponsoring clinical trial NCT01936480?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.